Pharmacotherapy in the Management of Pediatric Obesity (Q38667323)

5 September 2017

1 reference

title

Pharmacotherapy in the Management of Pediatric Obesity (English)

1 reference

5 September 2017

0 references

0 references

pediatric obesity

1 reference

Aaron S Kelly

1

1 reference

5 September 2017

Claudia K Fox

series ordinal

2

1 reference

5 September 2017

publication date

1 August 2017

1 reference

5 September 2017

published in

Current diabetes report

1 reference

5 September 2017

volume

17

1 reference

5 September 2017

issue

8

1 reference

5 September 2017

page(s)

55

1 reference

Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Metformin: new understandings, new uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effect of metformin on food intake in obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

AMPK: a key regulator of energy balance in the single cell and the whole organism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Metformin in obese children and adolescents: the MOCA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Systematic review of metformin use in obese nondiabetic children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Metformin for obesity in children and adolescents: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Meal replacements followed by topiramate for the treatment of adolescent severe obesity: A pilot randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11892-017-0886-Z

Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress.

21 January 2018

1 reference

12 December 2020

Central administration of metformin into the third ventricle of C57BL/6 mice decreases meal size and number and activates hypothalamic S6 kinase

1 reference

12 December 2020

Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials

1 reference

12 December 2020

Anorectic effect of metformin in lean and genetically obese hyperglycaemic (ob/ob) mice

1 reference

12 December 2020

Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up

1 reference

12 December 2020

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

12 December 2020

10.1007/S11892-017-0886-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1086127637

0 references

1 reference